The law offices of frank r. cruz announces investigation on behalf of aytu bioscience inc. investors (aytu)

Los angeles--(business wire)--the law offices of frank r. cruz announces an investigation on behalf of aytu bioscience inc. ("aytu" or the company") (nasdaq: aytu) investors concerning the company and its officers’ possible violations of federal securities laws. if you are a shareholder who suffered a loss, click here to participate. on march 10, 2020, aytu reported that it reached a license agreement for the exclusive distribution of a point-of-care rapid test for certain covid-19 antibodies in the u.s. for three years, with three year auto-renewals moving forward. then, on april 17, 2020, pre-market, nbc news issued a report entitled “unapproved chinese coronavirus antibody tests being used in at least 2 states.” citing health officials and u.s. food and drug administration (“fda”) filings, the article stated that the company has been distributing unreliable covid-19 tests from unapproved chinese manufacturers, which were shipped to the u.s. after the fda relaxed its guidelines for tests in mid-march. on this news, the company’s share price fell $0.12 per share, or 8%, to close at $1.38 per share on april 17, 2020, thereby injuring investors. follow us for updates on twitter: twitter.com/frc_law. if you purchased aytu securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact frank r. cruz, of the law offices of frank r. cruz, 1999 avenue of the stars, suite 1100, los angeles, california 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. if you inquire by email please include your mailing address, telephone number, and number of shares purchased. this press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules.
AYTU Ratings Summary
AYTU Quant Ranking